文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

肺转移患者接受立体定向放疗联合或不联合全身治疗的前瞻性免疫应答研究

A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment.
PubMed 文献 · Radiother Oncol · 2025-04-08

本研究前瞻性评估立体定向体部放疗(SBRT)对外周血免疫细胞的纵向影响,纳入100例寡转移/寡进展肺部病灶患者(80例可评估样本),比较联合全身治疗(cSBRT)与单纯SBRT。主要终点为首次随访时CD8+ T细胞较基线的增加,结果显示SBRT组12%、cSBRT组20%患者出现增加;中位随访30个月,中位OS分别为30个月和53个月。

要点

  • SBRT组12%、cSBRT组20%患者首次随访时CD8+ T细胞计数较基线增加。
  • 中位随访30个月,SBRT组中位OS 30个月 vs cSBRT组53个月。
  • 较低分次剂量显著增加增殖性CD4+和CD8+ T细胞比例。

核心结论

  • 在寡转移/寡进展疾病中,消融性SBRT的最佳剂量分次可能为每分次低于10 Gy,全身治疗的最佳时机可能为SBRT后以利用其免疫调节效应。

研究设计与样本

  • 前瞻性研究,纳入寡转移/寡进展肺部病灶患者,接受消融性SBRT联合(cSBRT)或不联合(SBRT组)全身治疗(化疗或免疫检查点阻断ICB),采用不同分次方案。
  • 在外周血基线、SBRT期间、SBRT结束时及第一(FU1)和第二(FU2)次随访时进行免疫谱分析。
  • 主要终点为FU1时CD8+ T细胞较基线的增加;研究入组100例患者,80例样本可评估。

主要发现

  • FU1时,SBRT组12%和cSBRT组20%的患者出现CD8+ T细胞计数增加。
  • 中位随访30个月,SBRT组中位OS为30个月,cSBRT组为53个月。
  • 较低分次剂量导致增殖性CD4+和CD8+ T细胞比例显著增加。
  • 增殖性T细胞自基线标准化变化的效应量在SBRT组更为显著。
  • T细胞增殖增加在治疗结束时明显,并在FU1(SBRT、cSBRT)和FU2(SBRT)维持;加用ICB未导致该全身免疫调节效应的增强。

关键数值与推荐

  • 主要终点FU1时CD8+ T细胞较基线增加:SBRT组12% vs cSBRT组20%。
  • 中位随访30个月,中位OS:SBRT组30个月 vs cSBRT组53个月。
  • 较低分次剂量(原文结论提及每分次低于10 Gy)与增殖性CD4+和CD8+ T细胞比例显著增加相关。

临床怎么用

  • 在寡转移/寡进展疾病中,消融性SBRT的最佳剂量分次可能为每分次低于10 Gy。
  • 全身治疗的最佳时机可能为SBRT后,以利用SBRT的免疫调节效应。
  • 加用ICB未导致该全身免疫调节效应的增强。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We evaluated the longitudinal effects of stereotactic body radiotherapy (SBRT) on circulating immune cells. MATERIALS AND METHODS: Patients with oligometastatic/oligoprogressive pulmonary lesions were treated with ablative SBRT with (cSBRT) or without (SBRT group) concurrent systemic treatment (chemotherapy or immune checkpoint blockade, ICB) using different fractionation regimes. Immunoprofiling of peripheral blood cells was performed at baseline, during, and at the end of SBRT, and during the first (FU1) and second follow-ups (FU2). The primary endpoint was the increase in CD8+ T cells at FU1 compared to baseline. RESULTS: The study accrued 100 patients, 80 with evaluable samples. At FU1 12 % and 20 % of the patients experienced an increase in CD8+ T-cell counts in the SBRT and cSBRT groups, respectively. With a median follow-up of 30 months, the median OS was 30 months in the SBRT group and 53 months for the cSBRT group. Lower doses per fraction led to a significant increase in the proportion of proliferating CD4+ and CD8+ T cells. The effect size of standardized changes from baseline in proliferating T cells was considerably more significant in the SBRT group. The increased T-cell proliferation was prominent at the end of treatment and maintained at FU1 (SBRT, cSBRT) and FU2 (SBRT). The addition of ICBs did not lead to an augmentation of this systemic immunomodulatory effect. CONCLUSION: In oligometastatic/oligoprogressive disease, the optimal dose and fractionation for ablative SBRT might be with less than 10 Gy per fraction and the optimal timing of systemic treatment may be post-SBRT to leverage the immune-modulating effects of SBRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gkika E, Firat E, Adebahr S, et al. A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment. Radiother Oncol. 2025. PMID: 40209858. doi:10.1016/j.radonc.2025.110889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。